The Food and Drug Administration has approved a drug therapy to help fight age related blindness.
The drug is called Macugen and it's the first drug proven to be effective for all subtypes of wet age-related macular degeneration, which can lead to blindness. The new drug attacks the rapid progression of wet AMD in which new blood vessels form behind the retina then leak and destroy central vision. Macugen is expected to be available sometime within the next 3 months.
Wet AMD affects more than one and a half million people over age 50. Some 6.3 million are expected to be affected by it over the next 20 years as the baby boomer generation ages.
For more information ( click here ).